secwatch.observer — SEC 8-K summary
======================================

Issuer:     KYNTRA BIO, INC. (KYNB)
CIK:        0000921299
Form:       8-K
Filed at:   2024-05-06T23:59:59+00:00
Accession:  0000950170-24-053533
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FibroGen Q1 2024 revenue up 55% YoY to $55.9M; net loss narrows to $32.9M
-------------------------------------------------------------------------

- Net loss of $32.9M ($0.33 per share) vs $76.7M loss ($0.81 per share) in Q1 2023.
- Roxadustat China net sales by FibroGen and JDE totaled $79.4M, up 24% YoY on 39% volume growth.
- Topline data for pamrevlumab in metastatic pancreatic cancer expected mid-2024; LAPIS Phase 3 data in 3Q 2024.
- Phase 1 FG-3246 (CD46 ADC) in mCRPC showed median rPFS of 8.7 months; 20% partial response rate.
- Cash and receivables $214.7M; runway into 2026; FY 2024 roxadustat revenue guidance reaffirmed $120-135M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/921299/000095017024053533/0000950170-24-053533-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/921299/000095017024053533/fgen-20240506.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-053533

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer